Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 1/2 3

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Carcinoma, Hepatocellular 2Glioblastoma 1Camurati-Engelmann Syndrome 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × LY-2157299 × Clear all
NCT01582269 2025-11-24

A Study in Recurrent Glioblastoma (GB)

Eli Lilly and Company

Phase 2 Completed
158 enrolled 20 charts
CNS

Glioblastoma

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
204 enrolled 27 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡